Abstract
Glioblastoma multiforme (GBM) is the most commonly diagnosed primary Central Nervous System tumors in adults, with approximately 10,000 new cases annually in the United States. GBMs rank among the deadliest of all human cancers with no curative options available; no meaningful therapeutic advances have been made in over 30 years. Recurrence is inevitable in the vast majority of cases, and a permanent cure for GBM remains elusive. Even those individuals who respond to first-line therapies subsequently exhibit a limited response to second-line therapies, which eventually leads to their demise. Therefore, there is an urgent need to develop novel therapeutic options that effectively target therapy-resistant GBM cells. GBM stem cells (GSCs) are a subpopulation of highly tumorigenic cells that contain stem cell characteristics. While our understanding of GSCs is evolving, studies support that GSCs drive GBM propagation and enable resistance to conventional therapies such as radiation. Identification of novel therapeutics designed to target the GSC population in GBM has emerged as a promising strategy to overcome this lethal disease. This review summarizes the latest understanding about translational research toward molecular characterization of GSCs and potential therapeutic application of the recent pre-clinical research discoveries to the clinic.
Keywords: Glioma, glioblastoma, cancer stem cell, therapeutic development, experimental therapeutics, Malignant brain tumors, glioblastoma or GBM)
Current Signal Transduction Therapy
Title:Overview of Brain Tumor Stem Cells – Implications for Treatment
Volume: 8 Issue: 1
Author(s): Joseph L. Lasky III and Ichiro Nakano
Affiliation:
Keywords: Glioma, glioblastoma, cancer stem cell, therapeutic development, experimental therapeutics, Malignant brain tumors, glioblastoma or GBM)
Abstract: Glioblastoma multiforme (GBM) is the most commonly diagnosed primary Central Nervous System tumors in adults, with approximately 10,000 new cases annually in the United States. GBMs rank among the deadliest of all human cancers with no curative options available; no meaningful therapeutic advances have been made in over 30 years. Recurrence is inevitable in the vast majority of cases, and a permanent cure for GBM remains elusive. Even those individuals who respond to first-line therapies subsequently exhibit a limited response to second-line therapies, which eventually leads to their demise. Therefore, there is an urgent need to develop novel therapeutic options that effectively target therapy-resistant GBM cells. GBM stem cells (GSCs) are a subpopulation of highly tumorigenic cells that contain stem cell characteristics. While our understanding of GSCs is evolving, studies support that GSCs drive GBM propagation and enable resistance to conventional therapies such as radiation. Identification of novel therapeutics designed to target the GSC population in GBM has emerged as a promising strategy to overcome this lethal disease. This review summarizes the latest understanding about translational research toward molecular characterization of GSCs and potential therapeutic application of the recent pre-clinical research discoveries to the clinic.
Export Options
About this article
Cite this article as:
L. Lasky III Joseph and Nakano Ichiro, Overview of Brain Tumor Stem Cells – Implications for Treatment, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010007
DOI https://dx.doi.org/10.2174/1574362411308010007 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets In Vitro Evaluation of Antimicrobial and Antiproliferative Activities for Compounds Isolated from the Ficus Bubu Warb. (Moraceae) Fruits: Chemotaxonomic Significance
Drug Delivery Letters Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions
CNS & Neurological Disorders - Drug Targets The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Patent Selections
Recent Patents on Biotechnology Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen
Current Pharmaceutical Design New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Aerosol Processing of Crumpled Graphene Oxide-based Nanocomposites for Drug Delivery
Current Pharmaceutical Design An Efficient Light-weight Network for Fast Reconstruction on MR Images
Current Medical Imaging Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Current Drug Targets Overview of Pediatric Epilepsy
Current Pediatric Reviews